close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Boehringer Ingelheim Limited

News headline image
The hidden impact of veterinary care: new insights from a global survey of veterinarians
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim and Eko Health Inc. launch new AI-based solution that detects heart murmurs in dogs
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK’s Knowledge Quarter
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Global survey reveals pet owners lack awareness of parasite risks and seek clearer prevention advice
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim announces appointment to Board of Managing Directors
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim obtains two EU CVMP positive opinions for avian influenza vaccines VAXXITEK® HVT+IBD+H5 and VAXXINACT® H5
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim and CDR-Life Expand Collaboration Efforts with Global Licensing Agreement for CDR111, an Antibody-Based Trispecific M-gager® for Autoimmune Diseases
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim launches new direct-to-consumer platform to expand patient access to important treatments
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
From Boehringer Ingelheim Limited
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today